Pay in 4 interest-free payments of $6.88 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Key findings across Phase II and III trials: Women receiving PT-141 showed statistically significant increases in satisfying sexual events per month compared to placebo Reduction in sexual distress scores was observed across multiple validated instruments Effects were noted within the first treatment cycle and maintained across the 12-week study period Response was not limited to any one demographic subgroup efficacy was consistent across age ranges within the premenopausal population Research Context for Male Sexual Dysfunction While PT-141s FDA approval is specifically for HSDD in women, substantial preclinical and Phase II research has examined its effects in men particularly in cases where psychological or neurological factors contribute to sexual dysfunction that vascular agents alone cannot address
Managing side effects through rotation Some people tolerate one medication better than the other
Resveratrol and exercise combined to treat functional limitations in late life: A pilot randomized controlled trial
These results reaffirm previous study conclusions about GSH, MDA, and cytokine levels between healthy and T2DM individuals ( Preclinical Results: Intracellular Survival of M
